Head to Head Analysis: TherapeuticsMD (TXMD) & Its Rivals

TherapeuticsMD (NASDAQ: TXMD) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare TherapeuticsMD to related businesses based on the strength of its risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

76.8% of TherapeuticsMD shares are held by institutional investors. Comparatively, 64.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 23.9% of TherapeuticsMD shares are held by company insiders. Comparatively, 10.7% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares TherapeuticsMD and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TherapeuticsMD -457.00% -65.16% -58.66%
TherapeuticsMD Competitors -547.39% -39.22% -21.47%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for TherapeuticsMD and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TherapeuticsMD 0 1 10 0 2.91
TherapeuticsMD Competitors 69 334 987 29 2.69

TherapeuticsMD currently has a consensus target price of $14.72, indicating a potential upside of 151.66%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 20.33%. Given TherapeuticsMD’s stronger consensus rating and higher possible upside, analysts clearly believe TherapeuticsMD is more favorable than its competitors.

Volatility & Risk

TherapeuticsMD has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, TherapeuticsMD’s competitors have a beta of 1.24, indicating that their average stock price is 24% more volatile than the S&P 500.

Earnings and Valuation

This table compares TherapeuticsMD and its competitors revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
TherapeuticsMD $19.36 million -$89.87 million -14.62
TherapeuticsMD Competitors $3.02 billion $642.98 million -30.13

TherapeuticsMD’s competitors have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

What are top analysts saying about TherapeuticsMD Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TherapeuticsMD Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit